SEC Company Response from Verrica Pharmaceuticals Inc. (VRCA) (CIK 0001660334) (VRCA) — Jun 12, 2018
Verrica Pharmaceuticals Inc. (VRCA) (CIK 0001660334)
Date: June 12, 2018 · CIK: 0001660334 · Accession: 0001193125-18-190381
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225104
Letter
June 12, 2018
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Christine Westbrook
Ms. Irene Paik
Ms. Bonnie Baynes
Ms. Angela Connell
Re: Verrica Pharmaceuticals Inc. (the “Company”)
Registration Statement on Form S-1
File No. 333-225104
Acceleration Request
Requested Date: Thursday, June 14, 2018
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
As representatives of the several underwriters of the Company’s proposed initial public offering, we hereby join the Company’s request that the effective date of the above-referenced Registration Statement be accelerated so that the above-referenced Registration Statement will be declared effective at 4:00 p.m., Eastern Time, on June 14, 2018, or as soon thereafter as is practicable.
Pursuant to Rule 460 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended, we wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus, dated June 5, 2018, through the date hereof:
Preliminary Prospectus dated June 5, 2018:
538 copies to prospective underwriters, institutional investors, dealers and others
The undersigned advises that it has complied and will continue to comply, and that it has been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of Page Intentionally Left Blank]
Very truly yours,
As representatives of the several underwriters
Show Raw Text
CORRESP 1 filename1.htm CORRESP June 12, 2018 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Christine Westbrook Ms. Irene Paik Ms. Bonnie Baynes Ms. Angela Connell Re: Verrica Pharmaceuticals Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-225104 Acceleration Request Requested Date: Thursday, June 14, 2018 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: As representatives of the several underwriters of the Company’s proposed initial public offering, we hereby join the Company’s request that the effective date of the above-referenced Registration Statement be accelerated so that the above-referenced Registration Statement will be declared effective at 4:00 p.m., Eastern Time, on June 14, 2018, or as soon thereafter as is practicable. Pursuant to Rule 460 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended, we wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus, dated June 5, 2018, through the date hereof: Preliminary Prospectus dated June 5, 2018: 538 copies to prospective underwriters, institutional investors, dealers and others The undersigned advises that it has complied and will continue to comply, and that it has been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Remainder of Page Intentionally Left Blank] Very truly yours, As representatives of the several underwriters MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED By: /s/ Richard A. Diaz Name: Richard A. Diaz Title: Authorized Signatory JEFFERIES LLC By: /s/ Matthew Kim Name: Matthew Kim Title: Managing Director COWEN AND COMPANY, LLC By: /s/ James Streator Name: James Streator, III Title: Managing Director [Signature Page to Underwriter Acceleration Request]